Q3 2024 CytomX Therapeutics Inc Earnings Call Transcript
Key Points
- CytomX Therapeutics Inc (CTMX) has over 15 active discovery and development programs, with three currently in Phase 1 clinical development.
- The company reported positive Phase 1A dose escalation data for CX-904, showing a favorable safety profile and early signs of anticancer activity.
- CX-2051 has shown excellent early progress in its Phase 1 study, with a favorable safety profile and rapid dose escalation.
- CytomX has initiated a Phase 1 clinical study for CX-801, with plans to explore its potential in combination with PD-1 inhibitors.
- The company ended the quarter with $118 million in cash, expected to fund operations through the end of 2025.
- The maximum tolerated dose for CX-904 has not yet been reached, delaying the decision to initiate Phase 1B until 2025.
- Operating expenses increased by $6.1 million compared to the third quarter of 2023, driven by higher clinical and manufacturing costs.
- The company does not expect any additional milestones from existing collaborations to be included in their cash guidance.
- There is a scarcity of good tumor targets for conventional unmasked T-cell engagers, posing challenges for development.
- The company is still in early stages for several programs, with significant clinical data readouts not expected until 2025.
Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded.
I would now like to hand the call over to your host for today. Chris Ogden CytomX, Chief Financial Officer. Please go ahead.
Thank you. Good afternoon and thank you for joining us.
Before we begin. I would like to remind everyone that during this call we will be making forward-looking statements because forward-looking statements relate to the future.
They are subject to inherent uncertainties and risks that are difficult to predict and many of which are outside our control.
Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov we do not take no obligation to update any forward-looking statements whether as a result of new information, future developments or otherwise.
Earlier this afternoon, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
